Drug
Tradipitant
Tradipitant: highest development phase Phase 3, developed by Vanda Pharmaceuticals. 11 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tradipitant NCT06138613 | Phase 3 | Motion Sickness |
| Tradipitant NCT04028492 | Phase 3 | Idiopathic Gastroparesis |
| Tradipitant NCT03568331 | Phase 3 | Atopic Dermatitis |
| Tradipitant NCT05903924 | Phase 3 | Motion Sickness |
| Tradipitant NCT06836557 | Phase 3 | Idiopathic Gastroparesis |
| Tradipitant NCT04140695 | Phase 3 | Atopic Dermatitis |
| Tradipitant NCT04327661 | Phase 3 | Motion Sickness |
| Tradipitant NCT07446439 | Phase 3 | Nausea and Vomiting |
| Tradipitant NCT06804603 | Phase 2 | Obesity |
| Tradipitant NCT04849559 | Phase 1/2 | Healthy Volunteer |
| tradipitant NCT02621385 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Tradipitant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.